thalidomide has been researched along with Gastrointestinal Hemorrhage in 62 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 9.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "to assess the efficacy of thalidomide in the treatment of relapsed or refractory bleeding secondary to gastrointestinal angiodysplasia." | 9.16 | Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. ( Bellido, F; Garrido, A; León, R; López, J; Márquez, JL; Sayago, M, 2012) |
| "This pilot study assesses the efficacy, safety, and side-effect of thalidomide in the treatment of patients with chronic gastrointestinal bleeding from angiodysplasias." | 9.14 | Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. ( Cirocco, M; Kamalaporn, P; Kandel, G; Kortan, P; Marcon, N; May, G; Saravanan, R, 2009) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 8.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 8.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 7.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| "Thalidomide seems to inhibit growth of intestinal angiodysplasias and may be useful for treatment of patients with bleeding related to angiodysplasias." | 7.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 5.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "Angiodysplasias are one of the reasons of gastrointestinal bleeding, whose origin is usually due to vascular malformations." | 5.43 | Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias. ( Cardaba Garcia, E; Hernando Verdugo, M; Izquierdo Navarro, Mdel C; Sanchez Sanchez, MT, 2016) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "Thalidomide is an effective and safe treatment agent for GIVM and its associated bleeding." | 5.37 | The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Xiao, SD, 2011) |
| "Angiodysplasias are a major cause of lower gastrointestinal bleeding in patients over the age of 60 years." | 5.35 | A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. ( Dabak, V; Kamboj, G; Kuriakose, P; Shurafa, M, 2008) |
| "Treatment with thalidomide seems an effective therapy for patients with frequently recurring gastrointestinal blood loss due to angiodysplasias who no longer tolerate conventional and invasive procedures due to their physical condition." | 5.33 | [Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias]. ( de Koning, DB; Drenth, JP; Friederich, P; Nagengast, FM, 2006) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 5.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| "to assess the efficacy of thalidomide in the treatment of relapsed or refractory bleeding secondary to gastrointestinal angiodysplasia." | 5.16 | Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. ( Bellido, F; Garrido, A; León, R; López, J; Márquez, JL; Sayago, M, 2012) |
| "Thalidomide is an effective and relatively safe treatment for patients with refractory bleeding from gastrointestinal vascular malformations." | 5.15 | Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Wei, W; Xiao, SD; Xu, CH, 2011) |
| "This pilot study assesses the efficacy, safety, and side-effect of thalidomide in the treatment of patients with chronic gastrointestinal bleeding from angiodysplasias." | 5.14 | Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. ( Cirocco, M; Kamalaporn, P; Kandel, G; Kortan, P; Marcon, N; May, G; Saravanan, R, 2009) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 4.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 4.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 3.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| "Thalidomide seems to inhibit growth of intestinal angiodysplasias and may be useful for treatment of patients with bleeding related to angiodysplasias." | 3.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| "Angiodysplasia is a rare, but important, cause of both overt and occult GI bleeding especially in the older patients." | 2.50 | Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. ( Al-Araji, SA; Ragunath, K; Sami, SS, 2014) |
| "Postoperative pathology confirmed Crohn's disease." | 1.48 | [The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula]. ( Guo, F; Li, JN; Li, XQ; Ma, ZQ; Qian, JM; Wang, YN; Xue, HD; Yang, AM; Zhou, WX, 2018) |
| "Thalidomide is an anti-angiogenic compound that may offer a potential option for management of refractory LVAD-related GIB." | 1.46 | Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients. ( Chan, LL; Kerk, KL; Lim, CP; Seng, BJJ; Sim, DKL; Sivathasan, C; Soon, JL; Tan, TE; Teo, LLY, 2017) |
| "Angiodysplasias are one of the reasons of gastrointestinal bleeding, whose origin is usually due to vascular malformations." | 1.43 | Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias. ( Cardaba Garcia, E; Hernando Verdugo, M; Izquierdo Navarro, Mdel C; Sanchez Sanchez, MT, 2016) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| " The patient was administered an increasing dosage of thalidomide, up to 300 mg/day, with thromboembolism prophylaxis for 3 months, with no clinical response." | 1.39 | [High-dose thalidomide for severe idiopathic obscure gastrointestinal bleeding in a patient at high-thrombotic risk]. ( Gonzalez-Santiago, JM; Martín-Noguerol, E; Martinez-Alcalá, C; Molina-Infante, J; Vara-Brenes, D, 2013) |
| "Thalidomide is an effective and safe treatment agent for GIVM and its associated bleeding." | 1.37 | The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Xiao, SD, 2011) |
| "Thalidomide was prescribed for its antiangiogenic properties." | 1.35 | The use of thalidomide in the management of bleeding from a gastric cancer. ( Lambert, K; Ward, J, 2009) |
| "Angiodysplasias are a major cause of lower gastrointestinal bleeding in patients over the age of 60 years." | 1.35 | A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. ( Dabak, V; Kamboj, G; Kuriakose, P; Shurafa, M, 2008) |
| "Treatment with thalidomide seems an effective therapy for patients with frequently recurring gastrointestinal blood loss due to angiodysplasias who no longer tolerate conventional and invasive procedures due to their physical condition." | 1.33 | [Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias]. ( de Koning, DB; Drenth, JP; Friederich, P; Nagengast, FM, 2006) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 1.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.61) | 18.2507 |
| 2000's | 24 (38.71) | 29.6817 |
| 2010's | 35 (56.45) | 24.3611 |
| 2020's | 2 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H | 5 |
| Wu, S | 1 |
| Tang, M | 1 |
| Zhao, R | 1 |
| Zhang, Q | 1 |
| Dai, Z | 1 |
| Gao, Y | 3 |
| Yang, S | 1 |
| Li, Z | 1 |
| Du, Y | 1 |
| Yang, A | 1 |
| Zhong, L | 1 |
| Lu, L | 1 |
| Xu, L | 1 |
| Shen, X | 1 |
| Liu, S | 1 |
| Zhong, J | 1 |
| Li, X | 2 |
| Lu, H | 1 |
| Xiong, H | 1 |
| Shen, Y | 1 |
| Gong, S | 1 |
| Xue, H | 2 |
| Ge, Z | 3 |
| Namdaran, P | 1 |
| Zikos, TA | 1 |
| Pan, JY | 1 |
| Banerjee, D | 2 |
| Heo, Y | 1 |
| Park, HS | 1 |
| Shin, CS | 1 |
| Yoo, KC | 1 |
| Kim, D | 1 |
| Lee, T | 1 |
| Becq, A | 1 |
| Rahmi, G | 1 |
| Perrod, G | 1 |
| Cellier, C | 1 |
| Seng, BJJ | 1 |
| Teo, LLY | 1 |
| Chan, LL | 2 |
| Sim, DKL | 1 |
| Kerk, KL | 1 |
| Soon, JL | 1 |
| Tan, TE | 2 |
| Sivathasan, C | 2 |
| Lim, CP | 2 |
| Nakamura, T | 1 |
| Ogo, T | 1 |
| Tahara, N | 1 |
| Fukui, S | 1 |
| Tsuji, A | 1 |
| Ueda, J | 1 |
| Fukumoto, Y | 1 |
| Nakanishi, N | 1 |
| Ogawa, H | 1 |
| Yasuda, S | 1 |
| Nardone, G | 1 |
| Compare, D | 1 |
| Martino, A | 1 |
| Rocco, A | 1 |
| Hude, I | 1 |
| Batinić, J | 1 |
| Kinda, SB | 1 |
| Pulanić, D | 1 |
| Wang, YN | 1 |
| Li, XQ | 1 |
| Guo, F | 1 |
| Yang, AM | 1 |
| Qian, JM | 1 |
| Li, JN | 1 |
| Xue, HD | 1 |
| Zhou, WX | 1 |
| Ma, ZQ | 1 |
| Imamura, T | 1 |
| Kinugawa, K | 1 |
| Uriel, N | 1 |
| Wang, XY | 1 |
| Chen, Y | 1 |
| Du, Q | 1 |
| Nagano, S | 1 |
| Mori, M | 1 |
| Kato, A | 1 |
| Ono, Y | 1 |
| Aoki, K | 1 |
| Arima, H | 1 |
| Takiuchi, Y | 1 |
| Tabata, S | 1 |
| Yanagita, S | 1 |
| Matsushita, A | 1 |
| Ishikawa, T | 1 |
| Imai, H | 1 |
| Takahashi, T | 1 |
| Sami, SS | 1 |
| Al-Araji, SA | 1 |
| Ragunath, K | 1 |
| Prince, SK | 1 |
| Forgeson, G | 1 |
| Moser, S | 1 |
| Tischer, A | 1 |
| Karpi, A | 1 |
| Schleicher, M | 1 |
| Stavjanik, S | 1 |
| Gschwantler, M | 1 |
| Bauditz, J | 6 |
| Draper, K | 1 |
| Kale, P | 1 |
| Martin, B | 1 |
| Kelly Cordero, R | 1 |
| Ha, R | 1 |
| Engelen, ET | 1 |
| van Galen, KP | 1 |
| Schutgens, RE | 1 |
| Boey, JP | 1 |
| Hahn, U | 1 |
| Sagheer, S | 1 |
| McRae, SJ | 1 |
| Bond, A | 1 |
| Ahmed, W | 1 |
| Izquierdo Navarro, Mdel C | 1 |
| Hernando Verdugo, M | 1 |
| Cardaba Garcia, E | 1 |
| Sanchez Sanchez, MT | 1 |
| Feng, N | 2 |
| Fu, S | 2 |
| Bian, Z | 1 |
| Lin, X | 1 |
| Yang, L | 1 |
| Fang, J | 2 |
| Zhao, Y | 1 |
| Zhang, Y | 1 |
| Dai, J | 1 |
| Lim, CH | 1 |
| Sim, D | 1 |
| Serralta de Colsa, D | 1 |
| Arjona Medina, I | 1 |
| García Marín, A | 1 |
| Sanz Sánchez, M | 1 |
| Turégano Fuentes, F | 1 |
| Alberto, SF | 1 |
| Felix, J | 1 |
| de Deus, J | 1 |
| Mimidis, K | 1 |
| Kaliontzidou, M | 1 |
| Tzimas, T | 1 |
| Papadopoulos, V | 1 |
| Lambert, K | 1 |
| Ward, J | 1 |
| Bowcock, SJ | 1 |
| Patrick, HE | 1 |
| Fernández Salazar, LI | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Galante, I | 1 |
| Aller de la Fuente, R | 1 |
| González Hernández, JM | 1 |
| Jimenez-Saenz, M | 1 |
| Romero-Vazquez, J | 1 |
| Caunedo-Alvarez, A | 1 |
| Maldonado-Perez, B | 1 |
| Gutierrez, JM | 1 |
| Nomikou, E | 1 |
| Tsevrenis, V | 1 |
| Gafou, A | 1 |
| Bellia, M | 1 |
| Theodossiades, G | 1 |
| Kamalaporn, P | 1 |
| Saravanan, R | 1 |
| Cirocco, M | 1 |
| May, G | 1 |
| Kortan, P | 1 |
| Kandel, G | 1 |
| Marcon, N | 1 |
| Almadi, M | 1 |
| Ghali, PM | 1 |
| Constantin, A | 1 |
| Galipeau, J | 1 |
| Szilagyi, A | 1 |
| Bélard, E | 1 |
| Foss, CH | 1 |
| Christensen, LA | 1 |
| Schmidt, P | 1 |
| Nøjgaard, C | 1 |
| Molina-Infante, J | 2 |
| Perez-Gallardo, B | 1 |
| Ge, ZZ | 3 |
| Chen, HM | 3 |
| Gao, YJ | 3 |
| Liu, WZ | 2 |
| Xu, CH | 1 |
| Tan, HH | 3 |
| Chen, HY | 2 |
| Wei, W | 1 |
| Fang, JY | 2 |
| Xiao, SD | 2 |
| Vega, J | 1 |
| Goecke, H | 1 |
| Rodríguez, Mde L | 1 |
| Vergara, MT | 1 |
| Garrido Serrano, A | 1 |
| León, R | 2 |
| Sayago, M | 2 |
| Márquez, JL | 2 |
| Garrido, A | 1 |
| López, J | 1 |
| Bellido, F | 1 |
| Pizarro Moreno, A | 1 |
| Garzón Benavides, M | 1 |
| Araujo Miguez, A | 1 |
| Bozada García, JM | 1 |
| Alam, MA | 1 |
| Sami, S | 1 |
| Babu, S | 1 |
| Martín-Noguerol, E | 1 |
| Martinez-Alcalá, C | 1 |
| Gonzalez-Santiago, JM | 1 |
| Vara-Brenes, D | 1 |
| Perez Botero, J | 1 |
| Burns, D | 1 |
| Thompson, CA | 1 |
| Pruthi, RK | 1 |
| Pérez-Encinas, M | 1 |
| Rabuñal Martínez, MJ | 1 |
| Bello López, JL | 1 |
| Shurafa, M | 2 |
| Kamboj, G | 2 |
| Schachschal, G | 1 |
| Wedel, S | 1 |
| Lochs, H | 3 |
| Silver, R | 1 |
| Karajeh, MA | 1 |
| Hurlstone, DP | 1 |
| Stephenson, TJ | 1 |
| Ray-Chaudhuri, D | 1 |
| Gleeson, DC | 1 |
| Kirkham, SE | 1 |
| Lindley, KJ | 1 |
| Elawad, MA | 1 |
| Blanshard, C | 1 |
| Shah, N | 1 |
| Craanen, ME | 1 |
| van Triest, B | 1 |
| Verheijen, RH | 1 |
| Mulder, CJ | 1 |
| de Koning, DB | 1 |
| Drenth, JP | 1 |
| Friederich, P | 1 |
| Nagengast, FM | 1 |
| Voderholzer, W | 1 |
| Heidt, J | 1 |
| Langers, AM | 1 |
| van der Meer, FJ | 1 |
| Brouwer, RE | 1 |
| Concha, R | 1 |
| Amaro, R | 1 |
| Barkin, JS | 1 |
| Dabak, V | 1 |
| Kuriakose, P | 1 |
| Wettstein, AR | 1 |
| Meagher, AP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)[NCT05570448] | 36 participants (Anticipated) | Interventional | 2022-02-15 | Recruiting | |||
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding[NCT04680195] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-12-14 | Not yet recruiting | ||
| The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study[NCT02301949] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn | ||
| A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Efficacy of Thalidomide for Refractory Small Intestinal Bleeding From Vascular Malformation[NCT02707484] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study[NCT00964496] | Phase 2 | 55 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Randomised, Double-blind, Placebo-controlled Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding[NCT02754960] | Phase 2 | 0 participants (Actual) | Interventional | 2010-03-31 | Withdrawn | ||
| Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure[NCT02622906] | Phase 2 | 24 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment. (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 13 |
| Iron-controlled Group | 0 |
The change from baseline in bleeding duration at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | days (Mean) |
|---|---|
| Thalidomide Group | 5.2 |
| Iron-controlled Group | 0.8 |
The Change from baseline in bleeding episodes at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | bleeding episodes (Mean) |
|---|---|
| Thalidomide Group | -9.36 |
| Iron-controlled Group | 1.41 |
The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | g/L (Mean) |
|---|---|
| Thalidomide Group | 3.06 |
| Iron-controlled Group | -0.01 |
Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | milliliter (Mean) |
|---|---|
| Thalidomide Group | -1585.71 |
| Iron-controlled Group | -28.57 |
Numbers of participants dependent on blood transfusions (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 3 |
| Iron-controlled Group | 13 |
The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 20 |
| Iron-controlled Group | 1 |
11 reviews available for thalidomide and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Argon Plasma Coagulation; Electrocoagulation; Embolization, | 2017 |
Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE).
Topics: Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Italy; Practice Guidelines as Topic; Progestero | 2018 |
Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device.
Topics: Anticoagulants; Blood Component Transfusion; Fish Oils; Gastrointestinal Hemorrhage; Heart Failure; | 2018 |
Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management.
Topics: Angiodysplasia; Electrocoagulation; Gastrointestinal Hemorrhage; Humans; Octreotide; Thalidomide | 2014 |
Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.
Topics: Aged; Angiodysplasia; Databases, Factual; Epistaxis; Female; Gastrointestinal Hemorrhage; Humans; Me | 2015 |
Thalidomide in angiodysplasia-related bleeding.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Human | 2015 |
Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations.
Topics: Angiogenesis Inhibitors; Animals; Gastrointestinal Hemorrhage; Humans; Risk Factors; Thalidomide; Tr | 2016 |
[Angiogenesis inhibitors for treatment of angiodysplasia-related gastrointestinal bleeding].
Topics: Angiodysplasia; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2009 |
Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Angiography; Animals; Antifibrinol | 2009 |
Obscure gastrointestinal bleeding: diagnostic and therapeutic approach.
Topics: Algorithms; Angiogenesis Inhibitors; Angiography; Antifibrinolytic Agents; Endoscopy, Digestive Syst | 2007 |
Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Thalidomide; Vascular | 2007 |
4 trials available for thalidomide and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.
Topics: Administration, Oral; Angiodysplasia; China; Double-Blind Method; Gastrointestinal Hemorrhage; Hemat | 2023 |
Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Blood Transfusion; Chronic Disease | 2009 |
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhag | 2012 |
47 other studies available for thalidomide and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices.
Topics: Adult; Aged; Arteriovenous Malformations; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart- | 2020 |
Successful Treatment of Life-Threatening Small Bowel Bleeding With Thalidomide After Living Donor Kidney Transplantation: A Case Report.
Topics: Aged; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Kidney | 2019 |
Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart-Assi | 2017 |
Thalidomide for Hereditary Hemorrhagic Telangiectasia With Pulmonary Arterial Hypertension.
Topics: Adolescent; Adult; Blood Transfusion; Echocardiography; Electrocardiography; Fatal Outcome; Female; | 2018 |
Successful Treatment of Recurrent Gastrointestinal Bleeding Due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide: Two Birds with One Stone
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Intestine, Small | 2018 |
[The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula].
Topics: Anastomosis, Surgical; Colon; Crohn Disease; Cutaneous Fistula; Digestive System Surgical Procedures | 2018 |
Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia.
Topics: Aged; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Stomach Diseases; Telan | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Bleeding from gastrointestinal tract recurrence of non-seminomatous germ cell tumour testis, showing temporary response to gemcitabine and oxaliplatin chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gastrointestinal Hemorrhage; G | 2013 |
Evidence that thalidomide is effective in recurrent bleeding from watermelon stomach associated with liver cirrhosis.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Gastric Antral Vascular Ectasia; Gastrointestina | 2014 |
[Effectiveness and security of thalidomide for gastrointestinal bleeding and severe Crohn's disease in children].
Topics: Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Immunosuppressi | 2014 |
Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol.
Topics: Adult; Aged; Angiodysplasia; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Gast | 2015 |
Thalidomide for the treatment of angiodysplasia in a patient with acute upper gastrointestinal haemorrhage.
Topics: Acute Disease; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Endoscopy; Female; Gastro | 2016 |
Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias.
Topics: Aged; Anemia; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Male; M | 2016 |
HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Basic Helix-Loo | 2016 |
Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Gastro | 2016 |
Novel Use of Thalidomide in Recurrent Gastrointestinal Tract Bleeding in Patients with Left Ventricular Assist Devices: A Case Series.
Topics: Aged; Angiogenesis Inhibitors; Cardiomyopathies; Dose-Response Relationship, Drug; Gastrointestinal | 2017 |
[Invalidating and recurrent gastrointestinal bleeding caused by intestinal angiodysplasia: treatment with thalidomide].
Topics: Aged; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Severity of Illness Ind | 2008 |
Thalidomide for the treatment of severe intestinal bleeding.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Gastrointestinal Hemorrhage | 2008 |
Thalidomide for treatment of bleeding angiodysplasias during hemodialysis.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Kidney Failure, | 2008 |
The use of thalidomide in the management of bleeding from a gastric cancer.
Topics: Aged; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Stomach Neoplasms; Thali | 2009 |
Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Chronic Disease; Female; Gastrointestinal Hemorrhage; | 2009 |
[Efficacy of thalidomide in digestive bleeding caused by angiodysplasias].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Cardiovascular Diseases; Cerebellar Neoplasms; Cerebe | 2009 |
Beneficial effects and reversion of vascular lesions by thalidomide in a patient with bleeding portal hypertensive enteropathy.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Compassionate Use Trials; Female; Gastrointestinal Hemorrha | 2010 |
Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide.
Topics: Angiodysplasia; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Thalidomide; von Willebran | 2009 |
[Thalidomide therapy for gastrointestinal angiodysplasia].
Topics: Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; R | 2009 |
Somatostatin analogues for bleeding gastrointestinal angiodysplasias: when should thalidomide be prescribed?
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Human | 2011 |
The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-2; Calcium-Binding Proteins; Gastrointestinal Hem | 2011 |
[Thalidomide for recurrent gastrointestinal bleeding caused by angiodysplasia: report of one case].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Intestines; Male | 2011 |
Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; | 2012 |
[Thalidomide associated to endoscopic treatment with argon plasma coagulation in rectal bleeding caused by vascular injury secundary to severe actinic proctitis].
Topics: Angiogenesis Inhibitors; Argon Plasma Coagulation; Chronic Disease; Gastrointestinal Hemorrhage; Hum | 2012 |
Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Diseases; Gastrointestinal H | 2011 |
[High-dose thalidomide for severe idiopathic obscure gastrointestinal bleeding in a patient at high-thrombotic risk].
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Risk Assess | 2013 |
Successful treatment with thalidomide for a patient with recurrent gastrointestinal bleeding due to angiodysplasia diagnosed by capsule endoscopy.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Female; Gastrointestinal Hemorrhag | 2013 |
Successful treatment with thalidomide of a patient with congenital factor V deficiency and factor V inhibitor with recurrent gastrointestinal bleeding from small bowel arteriovenous malformations.
Topics: Aged; Angiogenesis Inhibitors; Arteriovenous Malformations; Blood Coagulation Factor Inhibitors; Blo | 2013 |
Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Electrocoagulation; Gastrointestinal Hemorrhag | 2002 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Man | 2005 |
Refractory bleeding from portal hypertensive gastropathy: a further novel role for thalidomide therapy?
Topics: Angiogenesis Inhibitors; Biopsy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans | 2006 |
Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Angiography; Blood Transfusion; Capsule Endoscopy; Child; C | 2006 |
Thalidomide in refractory haemorrhagic radiation induced proctitis.
Topics: Aged; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Proctitis; Radiation Inj | 2006 |
[Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias].
Topics: Aged, 80 and over; Anemia, Iron-Deficiency; Angiodysplasia; Angiogenesis Inhibitors; Blood Transfusi | 2006 |
Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Disease Progres | 2006 |
Thalidomide as treatment for digestive tract angiodysplasias.
Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; L | 2006 |
A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Pi | 2008 |
Thalidomide in Crohn's disease.
Topics: Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Thalidomide; Tumor Necrosis | 1997 |